U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07118735) titled 'AHCC(R) as Immune Modulator in Cancer Patients Treated With Immunotherapy' on July 11.
Brief Summary: This is a prospective, double-blind, randomized, placebo-controlled trial to evaluate whether AHCC(R) (Active Hexose Correlated Compound) can enhance the effect of immunotherapy in liver cancer patients.
Study Start Date: Aug. 20
Study Type: INTERVENTIONAL
Condition:
Liver Cancer
Hepatocellular Carcinoma
Intervention:
DIETARY_SUPPLEMENT: A standardized extract of cultured Lentinula edodes mycelia (AHCC(R))
3 grams of AHCC(R) taken orally once daily for 6 months or until disease progression or intolerance
DIETARY_SUPPLEMENT: ...